[1] Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040[J]. J Hepatol, 2022,77(6):1598-1606. [2] Chen W, Chiang C L, Dawson L A. Efficacy and safety of radiotherapy for primary liver cancer[J]. Chin Clin Oncol, 2021,10(1):9. [3] Xie L, Qian Z, Xu J. Clinical intervention effect of TACE combined with 3DCRT in patients with primary liver cancer[J]. Am J Transl Res, 2021,13(7):7960-7967. [4] Song Q, Guo Y, Yao X, et al. Comparative study of evaluating the microcirculatory function status of primary small HCC between the CE (DCE-MRI) and non-CE (IVIM-DWI) MR perfusion imaging[J]. Abdom Radiol (NY), 2021,46(6):2575-2583. [5] Zhang T, Ding G, Wang H, et al. miR-497 targets VEGF signal pathway to regulate proliferation, invasion and migration of hepatocellular carcinoma cells: a primary study using DEC-MRI[J]. J BUON, 2021,26(2):418-428. [6] 孙祥林,由英宁,赵相轩,等. 基于T2WI的纹理分析在预测肝癌经导管肝动脉化疗栓塞术后早期复发的价值[J]. 磁共振成像,2021,12(8):22-26,32. [7] 邓琰. MRI纹理分析预测肝细胞癌TACE术后短期疗效的初步研究[D]. 湖北医药学院,2023. [8] 国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志,2022,38(2):288-303. [9] Llovet J M, Lencioni R. mRECIST for HCC: performance and novel refinements[J]. J Hepatol, 2020,72(2):288-306. [10] Li Q J, He M K, Chen H W, et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase Ⅲ trial[J]. J Clin Oncol, 2022,40(2):150-160. [11] Shao L, Wang X, Yu Y, et al. Comparative analysis of the efficacy and accuracy of magnetic resonance imaging (MRI) and contrast-enhanced CT for residual and new lesions after transcatheter arterial chemoembolization (TACE) in patients with primary liver cancer[J]. Transl Cancer Res, 2021,10(8):3739-3747. [12] Brown A M, Kassab I, Massani M, et al. TACE versus TARE for patients with hepatocellular carcinoma: overall and individual patient level meta analysis[J]. Cancer Med, 2023,12(3):2590-2599. [13] Dang Z, Jiang L, Huang F. Effect of bevacizumab administered prior to transarterial chemoembolization on the therapeutic effects of lenvatinib given post-TACE in primary liver cancer patients[J]. Int J Clin Pharmacol Ther, 2023,61(10):423-429. [14] 翁炜,吕秀玲,张倩倩,等. 基于磁共振影像组学技术对肝癌经肝动脉化疗栓塞术后短期疗效的预后价值分析[J]. 中华医学杂志,2020,100(11):828-832. [15] Zheng J, Du P Z, Yang C, et al. DCE-MRI-based radiomics in predicting angiopoietin-2 expression in hepatocellular carcinoma[J]. Abdom Radiol (NY), 2023,48(11):3343-3352. [16] Zhou Y, Zhou G, Zhang J, et al. DCE-MRI based radiomics nomogram for preoperatively differentiating combined hepatocellular-cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma[J]. Eur Radiol, 2022,32(7):5004-5015. [17] Berks M, Little R A, Watson Y, et al. A model selection framework to quantify microvascular liver function in gadoxetate-enhanced MRI: application to healthy liver, diseased tissue, and hepatocellular carcinoma[J]. Magn Reson Med, 2021,86(4):1829-1844. [18] Michallek F, Sartoris R, Beaufrere A, et al. Differentiation of hepatocellular adenoma by subtype and hepatocellular carcinoma in non-cirrhotic liver by fractal analysis of perfusion MRI[J]. Insights Imaging, 2022,13(1):81. [19] 高万春,李小军,陈金叶,等. 3.0 TMR动态增强扫描参数分析肝癌患者经导管肝动脉化疗栓塞术后疗效评估的价值研究[J]. 实用医院临床杂志,2020,17(2):210-213. [20] 陈天佑,袁敏,周粟,等. 3.0T动态增强磁共振灌注成像对小肝癌射频消融疗效评估的价值研究[J]. 介入放射学杂志,2022,31(2):154-159. [21] 王奕,韩涛,张志强,等. 血清微小核糖核酸-599与肝细胞肝癌TACE治疗预后的相关性[J]. 介入放射学杂志,2021,30(12):1265-1270. |